The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non–high-density lipoprotein (HDL) cholesterol level, which is driven by remnant cholesterol ...

Cardiovascular disease (CVD) is the leading cause of death globally, and combating this range of complex disorders presents numerous challenges. Scientists seek innovative approaches to address this ...

In a recent study published in The New England Journal of Medicine, researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia ...

RNA drugs are a new type of medicine that treat disease by influencing how cells use genetic information, rather than by ...

Biologists have discovered a new type of RNA-splicing regulation that helps to determine which protein-coding exons will be included in messenger RNA transcripts. RNA splicing is a cellular process ...

RNA interference – RNAi – functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking as a way to treat infections of bees by a commercially ...